NEW YORK (360Dx) – British diagnostics firm Oncimmune said today that it has made SmartGene the exclusive distributor of its EarlyCDT-Lung test in Poland.
Oncimmune's test measures levels of seven autoantibodies in patient blood to aid in the early detection of lung cancer. The company markets EarlyCDT-Lung both for detecting lung cancer before it can be picked up via imaging techniques and for helping to evaluate whether nodules detected via imaging are likely malignant or benign.
Under the terms of the deal, SmartGene will offer the test in Poland for an initial period of three years and must meet minimum sales commitments of £900,000 ($1.2 million) over the term of the contract. First sales are expected to begin in early 2018, Oncimmune said.
"This distribution agreement is our fourth in Europe and brings the total minimum sales commitments to £1.4 million," Oncimmune CEO Geoffrey Hamilton-Fairley said in a statement. "We anticipate the signing of a number of further agreements in Europe and beyond in the coming months as we continue to deliver on our strategy of generating revenues from our platform technology through multiple products, regions, and partners."
This year, Oncimmune has inked distribution deals for EarlyCDT-Lung covering Israel, South Korea, Denmark, Norway, and Sweden. And last year, it signed on Accu Reference to offer the test to physicians in 15 US states.